/DISREGARD RELEASE: Arkbio/

We are advised by Arkbio that journalists and other readers should disregard the news release, Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD, issued on Jan. 6, 2026 by Arkbio over PR Newswire, as the release contained inappropriate information.

Subscribe on LinkedIn

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.